PE20190476A1 - Compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica - Google Patents

Compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica

Info

Publication number
PE20190476A1
PE20190476A1 PE2019000346A PE2019000346A PE20190476A1 PE 20190476 A1 PE20190476 A1 PE 20190476A1 PE 2019000346 A PE2019000346 A PE 2019000346A PE 2019000346 A PE2019000346 A PE 2019000346A PE 20190476 A1 PE20190476 A1 PE 20190476A1
Authority
PE
Peru
Prior art keywords
alkyl
benzyl
treatment
substituted
compounds
Prior art date
Application number
PE2019000346A
Other languages
English (en)
Inventor
Lu Gao
Chungen Liang
Hongying Yun
Xiufang Zheng
Jianping Wang
Kun Miao
Bo Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20190476A1 publication Critical patent/PE20190476A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se refiere a nuevos derivados sulfonimidoilpurinonas, compuestos de formula (I): en la que R1 es alquilo C1-C6, entre otros; R2 es bencilo, estando dicho bencilo no sustituido o sustituidos seleccionados independientemente entre halogeno y alquilo C1-C6, entre otros; y R3 es -NR4R5, entre otros, R4 es alquilo C1-C6, R5 es (alquil C1-C6)2NCOO-alquiloC1-C6. Son compuestos preferidos de entre: 6-amino-9-bencil-N-metil-8-oxo-N-propil-2-(propilsulfonimidoil)purin-7-carboxamida; 6-amino-9-bencil-N-(2-metoxietil)-N-metil-8-oxo-2-(propilsulfonimidoil)purin-7-carboxamida. Dichos compuestos presentan actividad agonista de receptor de tipo Toll in vivo que detectan patogenos invasores y el posterior inicio de respuestas inmunologicas innatas; tambien se refiere a una composicion farmaceutica y es util en el tratamiento o la prevencion de enfermedades infecciosas como VHB o VHC.
PE2019000346A 2016-08-29 2017-08-28 Compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica PE20190476A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2016097140 2016-08-29
CN2017092653 2017-07-12

Publications (1)

Publication Number Publication Date
PE20190476A1 true PE20190476A1 (es) 2019-04-04

Family

ID=59738346

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000346A PE20190476A1 (es) 2016-08-29 2017-08-28 Compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica

Country Status (31)

Country Link
US (3) US10233184B2 (es)
EP (2) EP3865482A1 (es)
JP (2) JP7013467B2 (es)
KR (2) KR20220147702A (es)
CN (1) CN109641904B (es)
AU (3) AU2017320742B2 (es)
BR (1) BR112019003519A2 (es)
CA (1) CA3034148A1 (es)
CL (1) CL2019000512A1 (es)
CO (1) CO2019000932A2 (es)
CR (1) CR20190087A (es)
DK (1) DK3504210T3 (es)
ES (1) ES2867849T3 (es)
HR (1) HRP20210621T1 (es)
HU (1) HUE053944T2 (es)
IL (3) IL293475B1 (es)
MA (1) MA46038B1 (es)
MX (2) MX2019002129A (es)
MY (1) MY197408A (es)
NZ (1) NZ750604A (es)
PE (1) PE20190476A1 (es)
PH (1) PH12019500432A1 (es)
PL (1) PL3504210T3 (es)
PT (1) PT3504210T (es)
RS (1) RS61752B1 (es)
RU (1) RU2751349C2 (es)
SG (2) SG11201901633WA (es)
SI (1) SI3504210T1 (es)
TW (1) TWI671300B (es)
UA (1) UA124270C2 (es)
WO (1) WO2018041763A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3294740B1 (en) * 2015-05-08 2019-09-04 H. Hoffnabb-La Roche Ag Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
TWI671300B (zh) * 2016-08-29 2019-09-11 瑞士商赫孚孟拉羅股份公司 用於治療及預防病毒感染之新穎7–經取代磺醯亞胺醯基嘌呤酮化合物及衍生物
CN109715214B (zh) * 2016-09-13 2022-03-04 豪夫迈·罗氏有限公司 Tlr7激动剂和hbv衣壳组装抑制剂的组合治疗
CN111699187A (zh) 2018-02-12 2020-09-22 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的新的砜化合物和衍生物
CA3091950A1 (en) * 2018-02-28 2019-09-06 F. Hoffmann-La Roche Ag 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
BR112021004590A2 (pt) 2018-09-12 2021-05-25 Silverback Therapeutics, Inc. composições para o tratamento de doença com conjugados imunoestimuladores
MX2021009496A (es) 2019-02-08 2021-09-08 Progeneer Inc Complejo de colesterol-agonista del receptor 7 u 8 tipo larga distancia, y uso del mismo.
WO2021067644A1 (en) 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
AU2021231160A1 (en) 2020-03-02 2022-09-22 Progeneer Inc. Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
KR20230047361A (ko) 2020-07-01 2023-04-07 아르스 파마슈티컬스 인크. 항-asgr1 항체 접합체 및 이의 용도
CN116056725A (zh) 2020-08-04 2023-05-02 蛋白科技先鋒 活性位点暂时灭活的功能性药物与Toll样受体7或8激动剂的缀合物及其用途
US20230346924A1 (en) 2020-08-04 2023-11-02 Progeneer Inc. Mrna vaccine comprising adjuvant capable of kinetic control
US20230355750A1 (en) 2020-08-04 2023-11-09 Progeneer Inc. Kinetically acting adjuvant ensemble
CN114787165B (zh) * 2020-09-27 2023-02-28 上海维申医药有限公司 大环tlr7激动剂、其制备方法、药物组合物及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3485225D1 (de) * 1983-08-18 1991-12-05 Beecham Group Plc Antivirale guanin-derivate.
WO1998001448A1 (fr) 1996-07-03 1998-01-15 Japan Energy Corporation Nouveaux derives de purine
AUPO912997A0 (en) * 1997-09-11 1997-10-02 Commonwealth Scientific And Industrial Research Organisation Antiviral agents
NZ504800A (en) 1997-11-28 2001-10-26 Sumitomo Pharma 6-Amino-9-benzyl-8-hydroxy-purine derivatives and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases thereof
JPH11180981A (ja) * 1997-12-19 1999-07-06 Sumitomo Pharmaceut Co Ltd 複素環誘導体
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
JP4189048B2 (ja) 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
ATE443507T1 (de) * 2002-03-15 2009-10-15 Univ Wayne State Neue 2-amino-9-((2- hydroxymethyl)cyclopropylidenmethyl)-purine als antivirale mittel
BR0314761A (pt) * 2002-09-27 2005-07-26 Sumitomo Pharma Composto de adenina e seu uso
MX2007013780A (es) 2005-05-04 2008-02-05 Pfizer Ltd Derivados 2 amido-6-amino-8-oxo purina como moduladores del receptor como tipo peaje (toll) para el tratamiento del cancer y las infecciones virales tal como la hepatitis c.
DE102006053049A1 (de) 2006-11-10 2008-05-15 Daimler Ag Staufach mit einer Abdeckeinrichtung
NZ582090A (en) * 2007-06-29 2012-05-25 Gilead Sciences Inc Purine derivatives and their use as modulators of toll-like receptor 7
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
PT2364314E (pt) * 2008-12-09 2014-06-09 Gilead Sciences Inc Moduladores de recetores toll-like
US8962652B2 (en) * 2009-10-22 2015-02-24 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
US20110150836A1 (en) 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
US8501724B1 (en) * 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
WO2016023511A1 (zh) 2014-08-15 2016-02-18 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
EP3294740B1 (en) * 2015-05-08 2019-09-04 H. Hoffnabb-La Roche Ag Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
TWI671300B (zh) * 2016-08-29 2019-09-11 瑞士商赫孚孟拉羅股份公司 用於治療及預防病毒感染之新穎7–經取代磺醯亞胺醯基嘌呤酮化合物及衍生物

Also Published As

Publication number Publication date
IL264710B (en) 2021-07-29
AU2021204303B2 (en) 2022-05-12
NZ750604A (en) 2024-02-23
PT3504210T (pt) 2021-04-19
UA124270C2 (uk) 2021-08-18
EP3504210A1 (en) 2019-07-03
RU2019107957A (ru) 2020-09-29
AU2022204697A1 (en) 2022-07-21
RS61752B1 (sr) 2021-05-31
TWI671300B (zh) 2019-09-11
KR102459155B1 (ko) 2022-10-28
WO2018041763A1 (en) 2018-03-08
KR20220147702A (ko) 2022-11-03
MA46038B1 (fr) 2021-05-31
TW201819382A (zh) 2018-06-01
AU2017320742A1 (en) 2019-02-28
US20190256515A1 (en) 2019-08-22
IL284255B (en) 2022-07-01
SI3504210T1 (sl) 2021-08-31
JP7214900B2 (ja) 2023-01-30
IL284255A (en) 2021-07-29
MA46038A (fr) 2019-07-03
ES2867849T3 (es) 2021-10-21
PL3504210T3 (pl) 2021-07-05
EP3865482A1 (en) 2021-08-18
IL293475A (en) 2022-08-01
JP7013467B2 (ja) 2022-01-31
US10752630B2 (en) 2020-08-25
SG10202010520SA (en) 2020-11-27
US20180072730A1 (en) 2018-03-15
DK3504210T3 (da) 2021-04-26
CO2019000932A2 (es) 2019-02-08
SG11201901633WA (en) 2019-03-28
KR20190039829A (ko) 2019-04-15
JP2019526633A (ja) 2019-09-19
MY197408A (en) 2023-06-16
EP3504210B1 (en) 2021-02-24
BR112019003519A2 (pt) 2019-05-21
MX2019002129A (es) 2019-06-20
IL293475B1 (en) 2024-06-01
JP2022050632A (ja) 2022-03-30
AU2017320742B2 (en) 2021-08-05
US10233184B2 (en) 2019-03-19
CN109641904A (zh) 2019-04-16
CL2019000512A1 (es) 2019-07-12
CA3034148A1 (en) 2018-03-08
MX2021006902A (es) 2021-07-07
CN109641904B (zh) 2022-01-28
AU2021204303A1 (en) 2021-07-22
PH12019500432A1 (en) 2019-10-21
CR20190087A (es) 2019-04-30
US20200385387A1 (en) 2020-12-10
HUE053944T2 (hu) 2021-08-30
RU2019107957A3 (es) 2020-12-18
RU2751349C2 (ru) 2021-07-13
HRP20210621T1 (hr) 2021-05-28

Similar Documents

Publication Publication Date Title
PE20190476A1 (es) Compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica
CL2018003492A1 (es) Hepatitis b agentes antivirales.
CL2021001288A1 (es) Heterociclos funcionalizados como agentes antivirales
CL2018002528A1 (es) Agentes anti virales de la hepatitis b.
CY1124404T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 και μεθοδοι χρησης αυτων
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
PE20160686A1 (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infeccion por virus de la hepatitis b
EA202092896A1 (ru) Гетероциклические и гетероарильные соединения для лечения болезни гентингтона
UY37997A (es) Agentes antivirales contra la hepatitis b
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CL2016002179A1 (es) Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b.
PE20220567A1 (es) Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen
CU20180011A7 (es) Composiciones farmacéuticas que comprenden compuestos derivados de diaminopirido (3,2-d) como moduladores de receptor de tipo toll
ECSP12011684A (es) Inhibidores de los virus flaviviridae.
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
CL2013002299A1 (es) Compuestos derivados de heterociclos, inhibidores de la replicacion del virus de la hepatitis c; composicion farmaceutica que los comprende; util en el tratamiento de una infeccion por vhc. (divisional solicitud 689-2011).
EA201592126A1 (ru) 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
PE20191461A1 (es) Compuestos amida para el tratamiento del vih
MA37712B1 (fr) Inhibiteurs macrocycliques de virus flaviviridae
MX2010009995A (es) Heterociclos puenteados como inhibidores de la integrasa del virus de inmunodeficiencia humana.
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
PE20161379A1 (es) Nuevos compuestos macrociclicos
UY38383A (es) Heterociclos funcionalizados como agentes antivirales
EA201790758A1 (ru) Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге